In contrast, progression due to CLL occurs later with acquisition of mutations to BTK C481S and PLCγ2 (within the autoinhibitory domain) in approximately 80% of patients with late progression [51]. Here, PLCG2 is linked to B-cell chronic lymphocytic leukemia.